Table 2.
Real world effectiveness of trastuzumab biosimilars in retrospective studies.
| Biosimilar (Reference) |
Population (N) | Primary Outcome |
Primary Outcome Results |
|---|---|---|---|
| SB3 [33] |
NA (215) | tpCR | SB3 56% |
| SB3 [28] |
NA (67) | tpCR | SB3 50% vs. TRZ 58% (p = 0.532) |
| CT-P6 [31] |
NA (254) MET (103) |
tpCR PFS |
CT-P6 74.4% vs. TRZ 69.8% (p = 0.411) CT-P6 13.0 vs. TRZ 18.0 months (p = 0.976) |
| ABP 980 [32] |
NA (79) | tpCR | ABP 980 55% vs. TRZ 33–55% |
| MYL-1401O [34] |
NA (136) | tpCR | MYL-1401O 39% vs. TRZ 40.3% (p = 0.598) |
NA (neoadjuvant), MET (metastatic), tpCR (total pathological complete response), PFS (progression free survival), TRZ (reference trastuzumab).